Krystal Biotech (KRYS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
3 Apr, 2026Voting matters and shareholder proposals
Election of two Class III directors: Krish S. Krishnan and Christopher Mason, with board recommendation to vote in favor.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026, recommended for approval.
Advisory approval of named executive officer compensation, with board recommendation to vote in favor.
Approval of Non-Employee Director Compensation Policy, recommended by the board.
Provision for other business to be addressed as may properly come before the meeting.
Board of directors and corporate governance
Nominees for Class III director positions are Krish S. Krishnan and Christopher Mason.
Executive compensation and say-on-pay
Advisory vote on the compensation of named executive officers is included as a proposal.
Separate proposal to approve the Non-Employee Director Compensation Policy.
Latest events from Krystal Biotech
- Proxy covers director elections, auditor ratification, pay, and new director compensation policy.KRYS
Proxy filing3 Apr 2026 - Strong revenue growth and pipeline progress position the company for major milestones in 2026.KRYS
Corporate presentation16 Mar 2026 - ROW sales and pivotal trial progress position the company for strong 2026 growth.KRYS
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Record revenue and net income growth, global expansion, and major pipeline progress in 2025.KRYS
Q4 202517 Feb 2026 - Q3 2025 delivered $97.8M revenue, 96% margin, and global VYJUVEK expansion, boosting net income.KRYS
Q3 20253 Feb 2026 - Q2 net product revenue surged 55% to $70.3M, with 91% gross margin and $15.6M net income.KRYS
Q2 20242 Feb 2026 - Strong compliance, broad access, and pipeline advances support robust growth and global expansion.KRYS
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - KB301 delivers durable, meaningful wrinkle reduction and is advancing to Phase 2 for décolleté.KRYS
Study Result23 Jan 2026 - Strong U.S. launch, global expansion, and key clinical milestones drive growth outlook.KRYS
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026